Avalo Therapeutics (AVTX) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 5.6% versus a loss of 7.4%. Over five years, GYRE leads with a -88.7% price change compared with -99.8% for AVTX. Gyre Therapeutics is the larger company by market cap ($746.5 million vs $732.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | GYRE |
|---|---|---|
| Share price | $13.65 | $7.04 |
| Market cap | $732.05M | $746.48M |
| 1-day change | +1.64% | +4.14% |
| YTD return | -26.05% | -4.25% |
| 1-year return | -5.56% | -7.40% |
| 5-year return | -99.79% | -88.73% |
| Forward P/E | — | 117.33 |
| EPS (TTM) | $-4.31 | $-0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $24.27 | $9.42 |
| 52-week low | $12.51 | $5.44 |
| Distance from 52-week high | -43.76% | -25.27% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +222.93% | +165.20% |
| Average volume | 925.93K | 105.93K |
| Shares outstanding | 53.63M | 106.03M |
| Employees | 33 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
AVTX vs GYRE FAQ
Which is bigger, Avalo Therapeutics or Gyre Therapeutics?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $746.48M compared with $732.05M for Avalo Therapeutics (AVTX).
Which stock has performed better over the past year, AVTX or GYRE?
AVTX returned -5.56% over the past 12 months, compared with -7.40% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.